Blood biomarkers for prostate cancer detection and prognosis

Shahrokh F. Shariat, Jose A. Karam, Claus Roehrborn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s. Despite its remarkable performance as a marker for prostate cancer. PSA is not prostate cancer specific. PSA can be released by normal as well as hyperplastic prostate cells, which undermines the specificity of PSA for prostate cancer diagnosis. Hence, there is a need for new biomarkers that can detected prostate cancer and, in addition, distinguish indolent from biologically aggressive cancers. Moreover, the emergence of new therapeutic approaches for prostate cancer cannot flourish without more reliable set of markers to serve as prognosticators, targets and surrogate end points of disease progression and response to treatment. As the most useful clinical biomarkers are likely to be those assayed from blood, there is an increasing interest in profiling blood proteins. With recent advances in biotechnology such as high-throughput molecular analyses, many potential blood biomarkers have been identified and are currently under investigation.

Original languageEnglish (US)
Pages (from-to)449-461
Number of pages13
JournalFuture Oncology
Volume3
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Prostatic Neoplasms
Biomarkers
Prostate-Specific Antigen
Biotechnology
Disease Progression
Blood Proteins
Prostate
Neoplasms
Therapeutics

Keywords

  • Biomarker
  • Diagnosis
  • Nomogram
  • Prognosis
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Blood biomarkers for prostate cancer detection and prognosis. / Shariat, Shahrokh F.; Karam, Jose A.; Roehrborn, Claus.

In: Future Oncology, Vol. 3, No. 4, 08.2007, p. 449-461.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Karam, Jose A. ; Roehrborn, Claus. / Blood biomarkers for prostate cancer detection and prognosis. In: Future Oncology. 2007 ; Vol. 3, No. 4. pp. 449-461.
@article{e714253f64cc410cab7dc84deb8a49db,
title = "Blood biomarkers for prostate cancer detection and prognosis",
abstract = "Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s. Despite its remarkable performance as a marker for prostate cancer. PSA is not prostate cancer specific. PSA can be released by normal as well as hyperplastic prostate cells, which undermines the specificity of PSA for prostate cancer diagnosis. Hence, there is a need for new biomarkers that can detected prostate cancer and, in addition, distinguish indolent from biologically aggressive cancers. Moreover, the emergence of new therapeutic approaches for prostate cancer cannot flourish without more reliable set of markers to serve as prognosticators, targets and surrogate end points of disease progression and response to treatment. As the most useful clinical biomarkers are likely to be those assayed from blood, there is an increasing interest in profiling blood proteins. With recent advances in biotechnology such as high-throughput molecular analyses, many potential blood biomarkers have been identified and are currently under investigation.",
keywords = "Biomarker, Diagnosis, Nomogram, Prognosis, Prostate cancer",
author = "Shariat, {Shahrokh F.} and Karam, {Jose A.} and Claus Roehrborn",
year = "2007",
month = "8",
doi = "10.2217/14796694.3.4.449",
language = "English (US)",
volume = "3",
pages = "449--461",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Blood biomarkers for prostate cancer detection and prognosis

AU - Shariat, Shahrokh F.

AU - Karam, Jose A.

AU - Roehrborn, Claus

PY - 2007/8

Y1 - 2007/8

N2 - Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s. Despite its remarkable performance as a marker for prostate cancer. PSA is not prostate cancer specific. PSA can be released by normal as well as hyperplastic prostate cells, which undermines the specificity of PSA for prostate cancer diagnosis. Hence, there is a need for new biomarkers that can detected prostate cancer and, in addition, distinguish indolent from biologically aggressive cancers. Moreover, the emergence of new therapeutic approaches for prostate cancer cannot flourish without more reliable set of markers to serve as prognosticators, targets and surrogate end points of disease progression and response to treatment. As the most useful clinical biomarkers are likely to be those assayed from blood, there is an increasing interest in profiling blood proteins. With recent advances in biotechnology such as high-throughput molecular analyses, many potential blood biomarkers have been identified and are currently under investigation.

AB - Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s. Despite its remarkable performance as a marker for prostate cancer. PSA is not prostate cancer specific. PSA can be released by normal as well as hyperplastic prostate cells, which undermines the specificity of PSA for prostate cancer diagnosis. Hence, there is a need for new biomarkers that can detected prostate cancer and, in addition, distinguish indolent from biologically aggressive cancers. Moreover, the emergence of new therapeutic approaches for prostate cancer cannot flourish without more reliable set of markers to serve as prognosticators, targets and surrogate end points of disease progression and response to treatment. As the most useful clinical biomarkers are likely to be those assayed from blood, there is an increasing interest in profiling blood proteins. With recent advances in biotechnology such as high-throughput molecular analyses, many potential blood biomarkers have been identified and are currently under investigation.

KW - Biomarker

KW - Diagnosis

KW - Nomogram

KW - Prognosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=34547903643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547903643&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.4.449

DO - 10.2217/14796694.3.4.449

M3 - Article

C2 - 17661720

AN - SCOPUS:34547903643

VL - 3

SP - 449

EP - 461

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -